ABSTRACT Randomized trials showing that high-dose therapy with autologous stem cell transplant (ASCT) improved the overall survival (OS) in multiple myeloma (MM) excluded patients over age

65. To compare the outcomes of older adults with MM who underwent ASCT with non-transplant strategies, we identified 146 patients aged 65–77 with newly diagnosed MM seen in the Washington

University School of Medicine from 2000 to 2010. Survival among patients who did (_N_=62) versus did not (_N_=84) undergo ASCT was compared using Cox proportional hazards modeling,

controlling for comorbidities, Eastern Cooperative Oncology Group performance status (PS) and the propensity to undergo ASCT. Median age was 68 years (range 65–77). PS and comorbidities did

was associated with superior OS (HR for mortality 0.52 (95% CI 0.30–0.91), _P_=0.02). In a cohort of older adults with MM, undergoing ASCT was associated with a nearly 50% lower mortality,

after controlling for PS, comorbidities, stage and the propensity to undergo ASCT. Access through your institution Buy or subscribe This is a preview of subscription content, access via your

institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this

article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in

* Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS OUTCOMES WITH AUTOLOGOUS STEM CELL TRANSPLANT VS. NON-TRANSPLANT

THERAPY IN PATIENTS 70 YEARS AND OLDER WITH MULTIPLE MYELOMA Article 11 August 2020 SINGLE VERSUS TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA Article Open

access 05 December 2024 AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA PATIENTS AGED ≥ 75 TREATED WITH NOVEL AGENTS Article 04 December 2020 REFERENCES * Smith BD, Smith GL,

Hurria A, Hortobagyi GN, Buchholz TA . Future of cancer incidence in the United States: burdens upon an aging, changing nation. _J Clin Oncol_ 2009; 27: 2758–2765. Article  Google Scholar  *

Pulte D, Gondos A, Brenner H . Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. _Oncologist_ 2011; 16: 1600–1603. Article 

Google Scholar  * Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S _et al_. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in

older patients. _Leukemia_ 2014; 28: 1122–1128. Article  CAS  Google Scholar  * Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A _et al_. Review of 1027 patients with newly

diagnosed multiple myeloma. _Mayo Clin Proc_ 2003; 78: 21–33. Article  Google Scholar  * Klepin HD, Hurd DD . Autologous transplantation in elderly patients with multiple myeloma: are we

asking the right questions? _Bone Marrow Transplant_ 2006; 38: 585–592. Article  CAS  Google Scholar  * Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF _et al_. A

prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. _N Engl J Med_ 1996; 335: 91–97. Article  CAS 

Google Scholar  * Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K _et al_. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. _N Engl J Med_ 2003;

348: 1875–1883. Article  CAS  Google Scholar  * Roncon S, Barbosa IL, Campilho F, Lopes SM, Campos A, Carvalhais A . Mobilization and collection of peripheral blood stem cells in multiple

myeloma patients older than 65 years. _Transplant Proc_ 2011; 43: 244–246. Article  CAS  Google Scholar  * Cheikh ElJ, Kfoury E, Calmels B, Lemarie C, Stoppa A-M, Bouabdallah R _et al_. Age

at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma. _Hematol Oncol Stem Cell Ther_ 2011; 4: 30–36. Article  Google Scholar  *

Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM _et al_. Feasibility of autologous hematopoietic stem cell transplant in patients aged≥ 70 years with multiple myeloma. _Leuk Lymphoma_

2012; 53: 118–122. Article  CAS  Google Scholar  * Muta T, Miyamoto T, Fujisaki T, Ohno Y, Kamimura T, Kato K _et al_. Evaluation of the feasibility and efficacy of autologous stem cell

transplantation in elderly patients with multiple myeloma. _Intern Med_ 2013; 52: 63–70. Article  CAS  Google Scholar  * Piccirillo JF, Creech CM, Zequeira R, Anderson S, Johnston AS .

Inclusion of comorbidity into oncology data registries. _J Registry Manage_ 1999; 26: 66–70. Google Scholar  * Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET _et al_.

Toxicity and response criteria of the Eastern Cooperative Oncology Group. _Am J Clin Oncol_ 1982; 5: 649–655. Article  CAS  Google Scholar  * Launay-Vacher V, Chatelut E, Lichtman SM,

Wildiers H, Steer C, Aapro M _et al_. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. _Ann Oncol_ 2007; 18:

1314–1321. Article  CAS  Google Scholar  * Durie BG, Salmon SE . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features,

response to treatment, and survival. _Cancer_ 1975; 36: 842–854. Article  CAS  Google Scholar  * Greipp PR . International Staging System for Multiple Myeloma. _J Clin Oncol_ 2005; 23:

3412–3420. Article  Google Scholar  * Little R, Rubin DB . _Statistical Analysis with Missing Data_. J. Wiley & Sons: New York, NY, USA, 1987. Google Scholar  * Rosenbaum P, Rubin D .

The central role of the propensity score in observational studies for causal effects. _Biometrika_ 1983; 70: 41–55. Article  Google Scholar  * Liu J, Weinhandl ED, Gilbertson DT, Collins AJ

St, Peter WL . Issues regarding “immortal time” in the analysis of the treatment effects in observational studies. _Kidney Int_ 2012; 81: 341–350. Article  Google Scholar  * Boyko EJ .

Observational research — opportunities and limitations. _J Diabetes Complications_ 2013; 27: 642–648. Article  Google Scholar  * Merz M, Neben K, Raab MS, Sauer S, Egerer G, Hundemer M _et

al_. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. _Ann Oncol_ 2014; 25: 189–195. Article  CAS  Google Scholar 

* Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK _et al_. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a

matched pair analysis. _Am J Hematol_ 2008; 83: 614–617. Article  Google Scholar  * Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Leung N _et al_. Impact of age and serum creatinine

value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. _Bone Marrow Transplant_ 2007; 39: 605–611. Article  CAS  Google Scholar  * Krejci M,

Buchler T, Hajek R, Svobodnik A, Krivanova A, Pour L _et al_. Autologous bone marrow transplantation in multiple myeloma: a single centre experience of 23 patients. _Bone Marrow Transplant_

2005; 35: 159–164. Article  CAS  Google Scholar  * Lenhoff S, Hjorth M, Westin J, Brinch L, Backstrom B, Carlson K _et al_. Impact of age on survival after intensive therapy for multiple

myeloma: a population-based study by the Nordic Myeloma Study Group. _Br J Haematol_ 2006; 133: 389–396. Article  Google Scholar  * Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie

B _et al_. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple

myeloma (IFM 99–06): a randomised trial. _Lancet_ 2007; 370: 1209–1218. Article  CAS  Google Scholar  * Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M _et al_. Melphalan

200mg/m(2) versus melphalan 100mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. _Blood_ 2010; 115: 1873–1879. Article  CAS  Google Scholar  * Ozaki S,

Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H _et al_. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A

multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. _Acta Haematol_ 2014; 132: 211–219. Article  Google Scholar  * Katz S, Ford

AB, Moskowitz R, Jackson B, Jaffe M . Studies of Illness in the Aged: The Index of ADL. _JAMA_ 1963; 185: 914–919. Article  CAS  Google Scholar  * Lawton M, Brody E . Assessment of older

people: self-maintaining and instrumental activities of daily living. _Gerontologist_ 1969; 9: 179–986. Article  CAS  Google Scholar  * Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD,

Gross CP _et al_. Predicting Chemotherapy Toxicity in Older Adults With Cancer: a prospective multicenter study. _J Clin Oncol_ 2011; 29: 3457–3465. Article  CAS  Google Scholar  * Extermann

M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J _et al_. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients

(CRASH) score. _Cancer_ 2012; 118: 3377–3386. Article  Google Scholar  * Bringhen S, Mateos M-V, Zweegman S, Larocca A, Falcone AP, Oriol A _et al_. Age and organ damage correlate with poor

survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. _Haematologica_ 2013; 98: 980–987. Article  Google Scholar  * Kleber M, Ihorst G,

Terhorst M, Koch B, Deschler B, Wäsch R _et al_. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel

MM–comorbidity score. _Blood Cancer J_ 2011; 1: e35–e38. Article  CAS  Google Scholar  * Kleber M, Ihorst G, Groß B, Koch B, Reinhardt H, Wäsch R _et al_. Validation of the Freiburg

Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. _Clin Lymphoma Myeloma Leuk_ 2013; 13: 541–551.

Article  Google Scholar  * Jantunen E, Kuittinen T, Penttilä K, Lehtonen P, Mahlamäki E, Nousiainen T . High-dose melphalan (200mg/m2) supported by autologous stem cell transplantation is

safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocol. _Bone Marrow Transplant_ 2006; 37: 917–922. Article  CAS  Google

Scholar  * Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E _et al_. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma

but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. _Bone Marrow Transplant_ 2003; 31: 163–170.

Article  CAS  Google Scholar  * Reece DE, Bredeson C, Pérez WS, Jagannath S, Zhang M-J, Ballen KK _et al_. Autologous stem cell transplantation in multiple myeloma patients /=60 years of

age. _Bone Marrow Transplant_ 2003; 32: 1135–1143. Article  CAS  Google Scholar  * O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V _et al_. Predictive factors for survival in

myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. _Bone Marrow Transplant_ 2006; 37: 731–737. Article  CAS  Google Scholar  *

Offidani M, Leoni P, Corvatta L, Polloni C, Gentili S, Savini A _et al_. ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus

maintenance in elderly patients with de novo multiple myeloma. _Eur J Haematol_ 2010; 84: 474–483. Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS This publication was

made possible by the Grant nos KM1CA156708 and K12CA167540 through the National Cancer Institute (NCI) at the National Institutes of Health (NIH) and Grant nos UL1 TR000448 through the

Clinical and Translational Science Award (CTSA) program of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health. We acknowledge the support

of the Biostatistics Core, Siteman Comprehensive Cancer Center and NCI Cancer Center Support Grant _P30 CA091842._ AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Medicine,

Division of Medical Oncology, Washington University School of Medicine, St Louis, MO, USA T M Wildes, M Fiala, R Vij, K Stockerl-Goldstein & K R Carson * Rush University Medical College,

Chicago, IL, USA J D Finney * Division of Biostatistics, Washington University School of Medicine, St Louis, MO, USA F Gao * Mayo Clinic, Scottsdale, AZ, USA J Mikhael * Department of

Surgery, Washington University School of Medicine, St Louis, MO, USA G Colditz Authors * T M Wildes View author publications You can also search for this author inPubMed Google Scholar * J D

Finney View author publications You can also search for this author inPubMed Google Scholar * M Fiala View author publications You can also search for this author inPubMed Google Scholar *

F Gao View author publications You can also search for this author inPubMed Google Scholar * R Vij View author publications You can also search for this author inPubMed Google Scholar * K

Stockerl-Goldstein View author publications You can also search for this author inPubMed Google Scholar * K R Carson View author publications You can also search for this author inPubMed 

Google Scholar * J Mikhael View author publications You can also search for this author inPubMed Google Scholar * G Colditz View author publications You can also search for this author

inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to T M Wildes. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no conflict of interest. RIGHTS AND PERMISSIONS

Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Wildes, T., Finney, J., Fiala, M. _et al._ High-dose therapy and autologous stem cell transplant in older adults with multiple

myeloma. _Bone Marrow Transplant_ 50, 1075–1082 (2015). https://doi.org/10.1038/bmt.2015.106 Download citation * Received: 19 November 2014 * Revised: 04 February 2015 * Accepted: 23

February 2015 * Published: 11 May 2015 * Issue Date: August 2015 * DOI: https://doi.org/10.1038/bmt.2015.106 SHARE THIS ARTICLE Anyone you share the following link with will be able to read

this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative